Trending
- Zenition C-arm offers a reliable solution for RUH
- East Lancashire trust is first to install Agfa Valory DR room
- Sheffield Cancer Centre marks 50 years of treating women with rare womb cancer
- Open MRI scanner and AI-powered ultrasound machine to equip London walk-in clinic
- Dr Barnes becomes president of IPEM
- Canon Medical advocates for increased use of ultrasound imaging to help tackle NHS waiting lists
- Lumicare ONE’s high level probe disinfection is achieved using UV-C
- High level disinfection reduces the time spent dealing with preventable infections
- Ultrasound games and AI image recognition to feature on GE HealthCare’s stand
- Philips to showcase hands-on live scanning with new Compact 5500 ultrasound platform
Nuclear medicine theragnostics: walk before you run
Author(s): Dr Gopinath Gnanasegaran, Dr Shaunak Navalkissoor
Hospital: Royal Free London NHS Foundation Trust
Reference: RAD Magazine, 49, 580, 20
Excerpt: Theragnostic nuclear medicine is a much discussed topic in nuclear medicine and is currently discussed and debated in clinical oncology with great interest and optimism. Radionuclide theragnostics generally pairs diagnostic biomarkers with radiolabelled therapeutic agents that share a specific target within the diseased cells or tissues. The clinical indications are expanding, with evolving evidence. Incorporating radionuclide theragnostics in the cancer management algorithm might improve patient selection, predict treatment response and toxicity, and help prognostication. In addition, this could avoid expensive and frequent diagnostic and therapeutic procedures. On a positive note, there has been significant growth in the science and technology related to molecular imaging and therapy in theragnostic nuclear medicine. However, on a negative note, the most common hurdle would be the limited workforce and funding for smooth implementation and transition.